Login / Signup

Safety and efficacy of cytotoxic chemotherapy in hepatocellular carcinoma after first-line treatment with sorafenib.

Leonardo Gomes da FonsecaGuilherme Nader MartaMaria Ignez Freitas Melro BraghiroliAline Lopes ChagasFlair Jose CarrilhoPaulo Marcelo HoffJorge Sabbaga
Published in: BMC cancer (2018)
In accordance with previous studies, CCT had a notable rate of adverse events. The poor prognosis of this cohort suggests that CCT may not alter the natural history of HCC after sorafenib progression.
Keyphrases
  • poor prognosis
  • long non coding rna
  • locally advanced
  • case control
  • radiation therapy